- Home
- STTK vs TRVG Comparison
STTK vs TRVG Comparison
Compare STTK & TRVG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STTK
- TRVG
- Stock Information
- Founded
- STTK 2016
- TRVG 2005
- Country
- STTK United States
- TRVG Germany
- Employees
- STTK N/A
- TRVG N/A
- Industry
- STTK Biotechnology: Pharmaceutical Preparations
- TRVG EDP Services
- Sector
- STTK Health Care
- TRVG Technology
- Exchange
- STTK Nasdaq
- TRVG Nasdaq
- Market Cap
- STTK 173.6M
- TRVG 159.2M
- IPO Year
- STTK 2020
- TRVG N/A
- Fundamental
- Price
- STTK $3.74
- TRVG $1.77
- Analyst Decision
- STTK Strong Buy
- TRVG Buy
- Analyst Count
- STTK 3
- TRVG 4
- Target Price
- STTK $10.67
- TRVG $2.75
- AVG Volume (30 Days)
- STTK 129.3K
- TRVG 41.2K
- Earning Date
- STTK 11-07-2024
- TRVG 10-30-2024
- Dividend Yield
- STTK N/A
- TRVG N/A
- EPS Growth
- STTK N/A
- TRVG N/A
- EPS
- STTK N/A
- TRVG N/A
- Revenue
- STTK $4,123,999.00
- TRVG $503,102,968.00
- Revenue This Year
- STTK $164.45
- TRVG N/A
- Revenue Next Year
- STTK N/A
- TRVG $6.99
- P/E Ratio
- STTK N/A
- TRVG N/A
- Revenue Growth
- STTK 380.09
- TRVG N/A
- 52 Week Low
- STTK $1.33
- TRVG $1.61
- 52 Week High
- STTK $11.76
- TRVG $5.90
- Technical
- Relative Strength Index (RSI)
- STTK 52.85
- TRVG 25.95
- Support Level
- STTK $3.60
- TRVG $1.76
- Resistance Level
- STTK $3.82
- TRVG $1.81
- Average True Range (ATR)
- STTK 0.23
- TRVG 0.06
- MACD
- STTK 0.03
- TRVG -0.01
- Stochastic Oscillator
- STTK 64.91
- TRVG 39.02
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.
About TRVG trivago N.V.
trivago NV is a hotel search company focused on reshaping the way travelers search for and compare hotels while enabling hotel advertisers to grow their businesses by providing access to a broad audience of travelers through the company's websites and apps. The platform allows travelers to make informed decisions by personalizing their hotel search and providing access to a deep supply of hotel information and prices. The company operates in three operating segments namely the Americas, Developed Europe, and the Rest of the World. It derives a majority of revenue from the Developed Europe segment. The Developed Europe segment is comprised of Austria, Belgium, Denmark, Finland, France, Germany, Ireland, Italy, Luxembourg, Malta, the Netherlands, Norway, Portugal, Spain, Sweden, and others.